These studies demonstrate the universal nature of MDSC induction by human solid tumors and characterize two distinct MDSC subsets: CD33+HLA-DR(low)HIF1α+/STAT3+ and CD11b+HLA-DR(low)C/EBPβ+, which should enable the development of novel diagnostic and therapeutic reagents for cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Lechner et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: